Shares of biopharmaceutical company PTC Therapeutics (NASDAQ:PTCT) are tanking today after it announced a halt to the Phase 2 study of PTC518 for treating Huntington’s disease.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The development comes after the U.S. Food and Drug Administration (FDA) asked for additional data before allowing the trial to proceed in the U.S.
The company remains in discussions with the FDA and aims to share data from the 12-week part of the study in H1 2023.
Read full Disclosure
